Trial Profile
A Phase 3 Study of CS-8958 (Prophylaxis of Single Administration) - A randomized, double-blind, placebo-controlled study to evaluate the efficacy of single dose administration for the prevention of influenza virus infection -
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Laninamivir (Primary)
- Indications Influenza virus infections
- Focus Therapeutic Use
- Sponsors Daiichi Sankyo Company
- 07 Jun 2016 New trial record